Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*

Trop-2 is a novel target for ADC therapy because of its high expression by many solid cancers. The rational development of IMMU-132 represents a paradigm shift as an ADC that binds a well-known moderately-cytotoxic drug, SN-38, to the anti-Trop-2 antibody. In vitro and in vivo studies show enhanced...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget
Main Authors: Goldenberg, David M., Cardillo, Thomas M., Govindan, Serengulam V., Rossi, Edmund A., Sharkey, Robert M.
Format: Artigo
Language:Inglês
Published: Impact Journals LLC 2015
Subjects:
Research Paper
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4673178/
https://ncbi.nlm.nih.gov/pubmed/26101915
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items